33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Analyze analyst forecasts for the company and compare them with competitors.
639.16M
The estimated revenue has increased from the previous period.
-407.40M
The estimated EBITDA has decreased from the previous period.
-0.16
The estimated EPS has increased from the previous period.
-86.44M
The estimated net income has increased from the previous period.
-458.30M
The estimated EBIT has decreased from the previous period.
719.58M
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
249.91M
Revenue has increased from the previous period.
108.49%
Revenue growth rate has increased from the previous period.
-185.21M
EBITDA has increased from the previous period.
-74.11%
EBITDA margin has increased from the previous period.
-222.32M
EBIT has increased from the previous period.
-88.96%
EBIT margin has increased from the previous period.
37.11M
Depreciation has increased from the previous period.
399.89M
Total cash has increased from the previous period.
160.02%
Cash percentage has decreased from the previous period.
42.25M
Receivables have increased from the previous period.
16.91%
Receivables percentage has decreased from the previous period.
13.67M
Inventories have decreased from the previous period.
5.47%
Inventory percentage has decreased from the previous period.
19.40M
Accounts payable has increased from the previous period.
7.76%
Payables percentage has decreased from the previous period.
-32.10M
Capital expenditure has increased from the previous period.
-12.85%
CapEx percentage has decreased from the previous period.
11.55%
WACC is unchanged from the previous period.
11.58%
Cost of equity is unchanged from the previous period.
4.40%
Cost of debt is unchanged from the previous period.
1.52
Beta is unchanged from the previous period.
534.88M
Diluted shares outstanding is unchanged from the previous period.
99.49M
Total debt is unchanged from the previous period.
23.34B
Total equity is unchanged from the previous period.
23.44B
Total capital is unchanged from the previous period.
0.42%
Debt weighting is unchanged from the previous period.
99.58%
Equity weighting is unchanged from the previous period.
-222.41M
EBIAT has increased from the previous period.
-219.66M
UFCF has increased from the previous period.
2.00%
Long-term growth rate is unchanged from the previous period.
-99.35B
Terminal value is unchanged from the previous period.
-71.64B
Enterprise value is unchanged from the previous period.
-36.05M
Net debt is unchanged from the previous period.
-71.60B
Equity value is unchanged from the previous period.
-133.86
Equity value per share is unchanged from the previous period.
View analysts' price targets and recommendations, and compare them with competitors.
$49.00
Lower upside than BRZE's upside of 77.52%.
Buy
Equal to BRZE's analyst recommendation of Buy.
